US · Healthcare · Biotechnology
EPS came in at -0.78 against a street estimate of -0.70 — a miss of 11.4%.
Analysts rate Alumis Inc a strong buy (9 buy, 1 hold, 0 sell out of 10) with an average price target of $32.12.
| Fund | Stake |
|---|---|
| BlackRock Inc | 6.35% |
| FMR Inc | 5.23% |
| Deep Track Capital, LP | 4.90% |
| Samsara BioCapital, LLC | 4.90% |
| Foresite Capital Management V, LLC | 4.56% |
| T. Rowe Price Associates, Inc. | 4.02% |
| venBio Partners LLC | 3.50% |
| Foresite Capital Management VI LLC | 3.28% |
| Document | Date |
|---|---|
| Company announcement · Q3 2026 ALUMIS INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Company: Alumis Inc. (NASDAQ: ALMS), Delaware-incorporated biopharmaceutical company • Report Date | 2026-09-01 |
| Quarterly report · Q2 2026 ALUMIS INC. — Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash and marketable securities: $502.3 million as of June 30, 2026 (cash $63.7M + marketable s | 2026-08-13 |
| Results announced · Q3 2026 ALUMIS INC. – Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash Position: $502.3 million in cash, cash equivalents, and marketable securities as of | 2026-08-13 |
| Company announcement · Q3 2026 ALUMIS INC. (ALMS) — FORM 8-K SUMMARY HEADLINE NUMBERS • Company: Alumis Inc., Delaware corporation, traded on Nasdaq Global Select Market under tic | 2026-08-10 |
| Shareholder vote results · Q2 2026 ALUMIS INC. (ALMS) – FORM 8-K SUMMARY HEADLINE NUMBERS • Outstanding shares as of record date (May 5, 2026): 123,432,072 shares of voting common sto | 2026-07-02 |
| Proxy statement · Q2 2026 ALUMIS INC. - 2026 PROXY STATEMENT SUMMARY HEADLINE NUMBERS • Annual Meeting scheduled for June 30, 2026 at 9:00 a.m. Pacific Time (virtual format v | 2026-05-18 |
| Quarterly report · Q1 2026 ALUMIS INC. — QUARTERLY REPORT SUMMARY Q1 2026 (Period Ended March 31, 2026) --- HEADLINE NUMBERS • Cash and Marketable Securities: $569.5 million | 2026-05-14 |
| Annual report FY2025 ALUMIS INC. — FORM 10-K SUMMARY (December 31, 2025) HEADLINE NUMBERS • Company is a clinical-stage biopharmaceutical firm with no approved products | 2026-03-19 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Alumis Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.